Consensus Vertex Pharmaceuticals Incorporated

Stocks

VRTX

US92532F1003

Pharmaceuticals

Market Closed - Nasdaq 01:30:00 21/10/2026 am IST			5-day change	1st Jan Change
514.65 ^USD	+2.53%		+6.07%	+13.52%

15/10	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653	MT
09/10	Vertex Pharmaceuticals Says Alyftrek Delivers Pancreatic Function Recovery in Some Children	MT

Evolution of the Average Target: Vertex Pharmaceuticals Incorporated

Evolution of the Target Price: Vertex Pharmaceuticals Incorporated

Changes in Analyst Recommendations: Vertex Pharmaceuticals Incorporated

e0914eca0.qD6ML34qlBHN-g7ZOBAPOXO0owTmKh8hH7tbKbKLR9M.wVveaCof1naGvGevZ1h7AEDBxme1cCxtKohsSMD4CLKcU7R-BF-gXviAaQ~c52d45e51dd6cb67d877a109a8acdf77

Analysts' recommendations: Vertex Pharmaceuticals Incorporated

15/10	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653	MT
08/10	RBC Lifts Price Target on Vertex Pharmaceuticals to $576 From $570, Keeps Outperform Rating	MT
28/09	UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating	MT
23/09	TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
23/09	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $640 From $633, Maintains Buy Rating	MT
02/09	Evercore ISI Adjusts Vertex Pharmaceuticals Price Target to $600 From $535, Maintains Outperform Rating	MT
12/08	Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says	MT
11/08	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating	MT
11/08	Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $556 From $555, Maintains Buy Rating	MT
05/08	Rothschild & Co Redburn Adjusts Vertex Pharmaceuticals Price Target to $580 From $570	MT
04/08	Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says	MT
04/08	Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says	MT
04/08	RBC Capital Adjusts Price Target on Vertex Pharmaceuticals to $570 From $577, Maintains Outperform Rating	MT
04/08	Barclays Adjusts PT on Vertex Pharmaceuticals to $617 From $615, Maintains Overweight Rating	MT
04/08	Goldman Sachs Adjusts PT on Vertex Pharmaceuticals to $653 From $652, Maintains Buy Rating	MT
04/08	Stifel Adjusts Price Target on Vertex Pharmaceuticals to $500 From $466, Maintains Hold Rating	MT
04/08	Cantor Fitzgerald Adjusts PT on Vertex Pharmaceuticals to $595 From $590, Maintains Overweight Rating	MT
04/08	Canaccord Genuity Adjusts PT on Vertex Pharmaceuticals to $442 From $436, Maintains Hold Rating	MT
04/08	TD Cowen Adjusts Price Target on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
21/07	Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19	MT
20/07	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating	MT
13/07	UBS Adjusts Vertex Pharmaceuticals Price Target to $585 From $545, Maintains Buy Rating	MT
09/07	RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $577 From $570	MT
08/07	Jefferies Adjusts Vertex Pharmaceuticals Price Target to $610 From $580	MT
07/07	Vertex Pharmaceuticals' Acquisition of Crinetics Adds Rare-Disease Drugs, UBS Says	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	VERTEX PHARMACEUTICALS INCORPORATED					+13.85%
	ELI LILLY AND COMPANY					+7.22%
	JOHNSON & JOHNSON					+10.09%
	ABBVIE INC.					-0.03%
	ROCHE HOLDING AG					+1.02%
	MERCK & CO., INC.					+10.39%
	NOVARTIS AG					-0.24%
	ASTRAZENECA PLC					+27.41%
	AMGEN INC.					-7.05%
	GILEAD SCIENCES, INC.					+4.63%
	Average					+6.73%
	Weighted average by Cap.					+6.50%